Gender and endothelial progenitor cell number in middle-aged adults

SummaryBackgroundBetween the ages of 45 and 65 years, the prevalence of cardiovascular disease is significantly lower in women compared with men. Circulating bone marrow-derived endothelial progenitor cells (EPCs) play an important role in vascular repair. Reduced EPC number is predictive of more cardiovascular events. It is currently unknown whether there is a sex-difference in EPC number in middle-aged adults.ObjectiveWe tested the hypothesis that circulating EPC number is higher in middle-aged women than men.MethodsPeripheral blood samples were collected from 58 sedentary adults, 29 men (57 ± 1 years) and 29 women (58 ± 1 years). Mononuclear cells were isolated and fluorescence-activated cell sorting (FACS) analysis of cells negative for CD45 was performed for those positive for CD34, and triple positive for CD34, VEGFR-2, and CD133 according to the recommendations of the International Society for Hematotherapy and Graft Engineering.ResultsThe number of CD45−/CD34+ and CD45−/CD34+/VEGFR-2+/CD133+ was not significantly different between women and men (0.055 ± 0.006% vs 0.069 ± 0.008% and 0.0013 ± 0.0003% vs 0.0018 ± 0.0004%, respectively).ConclusionsThese results demonstrate no sex-difference in EPC number in middle-age adults. Therefore, it is unlikely that differences in EPC number contribute to the gender-related differences in the prevalence of cardiovascular events in this population.